INS and type 2 diabetes mellitus: Sodium glucose cotransporter type 2 (SGLT2) inhibitors represent a new class of anti-hyperglycemic agents for T2DM, which act insulin-independently to selectively inhibit renal glucose reabsorption, thereby increasing urinary glucose excretion.